Literature DB >> 28673539

Trial designs and results supporting treatment de-escalation and escalation.

Meredith M Regan1, William T Barry2.   

Abstract

Trials for escalation and de-escalation of treatment aim to improve patient care, but from different sides of the same coin with respect to disease control and burdens of treatment. De-escalation of therapy is inherently a non-inferiority question. A design with random assignment to standard of care versus de-escalated therapy is typically implemented but ordinarily will require a large sample size. Some research questions of treatment de-escalation might be asked in select patient populations using single-arm designs. Trials of therapy escalation may better inform the care of individual patients by posing a clinically-oriented research question in an enriched patient population, or by planning analyses that exploit the heterogeneity of a broadly-defined enrolled population.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant therapy; Clinical trials; Non-inferiority

Mesh:

Substances:

Year:  2017        PMID: 28673539     DOI: 10.1016/j.breast.2017.06.020

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  3 in total

Review 1.  Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.

Authors:  Miriam Alb; Brigitte Anliker; Silvia Arcangeli; Chiara Bonini; Biagio De Angelis; Rashmi Choudhary; David Espie; Anne Galy; Cam Holland; Zoltán Ivics; Chahrazade Kantari-Mimoun; Marie Jose Kersten; Ulrike Köhl; Chantal Kuhn; Bruno Laugel; Franco Locatelli; Ibtissam Marchiq; Janet Markman; Marta Angiola Moresco; Emma Morris; Helene Negre; Concetta Quintarelli; Michael Rade; Kristin Reiche; Matthias Renner; Eliana Ruggiero; Carmen Sanges; Hans Stauss; Maria Themeli; Jan Van den Brulle; Emmanuel Donnadieu; Maik Luu; Michael Hudecek; Monica Casucci
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

2.  Adjuvant chemotherapy for node negative, high Recurrence ScoreTM breast cancer: in defense of de-escalation.

Authors:  Diana Lake; Andrew D Seidman
Journal:  NPJ Breast Cancer       Date:  2019-08-12

3.  Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trial.

Authors:  Zhuoxin Sun; Samuel M Niman; Olivia Pagani; Ann H Partridge; Hatem A Azim; Fedro A Peccatori; Monica Ruggeri; Angelo Di Leo; Marco Colleoni; Richard D Gelber; Meredith M Regan
Journal:  Breast       Date:  2020-06-02       Impact factor: 4.380

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.